Document Detail

Gut gavage with antiendotoxin antibodies reduces the liberation of tumor necrosis factor-alpha after hemorrhage/resuscitation.
MedLine Citation:
PMID:  10921574     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To evaluate the effect of gut gavage both alone and with enteral administration of monoclonal antibodies to endotoxin on the liberation of tumor necrosis factor (TNF)-alpha and subsequent hemodynamics after hemorrhage/resuscitation. DESIGN: Dose response intervention, sham-controlled animal study. SETTING: Research laboratory at a university medical center. ANIMALS: Instrumented rats (250-325 g body weight) underwent standardized hemorrhage/resuscitation. INTERVENTIONS: Animal groups received 4 hrs before hemorrhage/resuscitation: gastric gavage with Colyte alone (group 1), combined with E5 antiendotoxin at either 0.2 mg/100 g (group 2) or 2 mg/100 g body weight (group 3), or sham controls (group 4). There were six animals studied in each of the four groups. MEASUREMENTS AND MAIN RESULTS: For animals receiving gut gavage and high-dose E5 antiendotoxin, plasma concentrations of TNF-alpha (pg/mL) at 120 mins after hemorrhage/resuscitation were significantly lower compared with sham controls (16+/-4 group 3; 65+/-36 group 4; mean +/- SD, p < .05). At 300 mins, this same treatment group had a significantly higher mean blood pressure (mm Hg) (110+/-6 group 3; 86+/-7 group 4: p < .05). Also at 300 mins after hemorrhage/resuscitation, plasma lactate concentrations (mmol/L) were significantly lower for all gut gavage treatment groups compared with sham control animals (1.9+/-0.2 group 1; 2.0+/-0.2 group 2; 1.8+/-0.2 group 3; 4.8+/-2.8 group 4, p < .05). CONCLUSIONS: Prior treatment with gut gavage and enterally administered antiendotoxin antibodies reduces TNF-alpha liberation after hemorrhage/resuscitation and confers a subsequent improvement in hemodynamics and decreased plasma lactate concentrations. Such therapy may be efficacious in patients undergoing elective procedures where major hemorrhage is likely or in severely injured patients with continued or recurrent hemorrhage.
D C Gore; G Sutherland
Related Documents :
19796884 - Complications following linear accelerator based stereotactic radiation for cerebral ar...
8622154 - The role of radiosurgery and particulate embolization in the treatment of dural arterio...
8177384 - Treatment of hypertensive cerebellar hemorrhage--surgical or conservative management?
25226004 - A randomized, split-face, histomorphologic study comparing a volumetric calcium hydroxy...
17917734 - Effectiveness of colorectal laparoscopic surgery on patients at high anesthetic risk: a...
19652254 - Initial experience with the new amplatzer duct occluder ii.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Critical care medicine     Volume:  28     ISSN:  0090-3493     ISO Abbreviation:  Crit. Care Med.     Publication Date:  2000 Jul 
Date Detail:
Created Date:  2000-08-16     Completed Date:  2000-08-16     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0355501     Medline TA:  Crit Care Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2425-8     Citation Subset:  AIM; IM    
Department of Surgery, the University of Texas Medical Branch, Galveston, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / administration & dosage*
Endotoxins / immunology*
Gastric Lavage*
Hemorrhage / therapy*
Lactates / blood*
Rats, Sprague-Dawley
Resuscitation / methods
Tumor Necrosis Factor-alpha / metabolism*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Endotoxins; 0/Lactates; 0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Combined therapy with zaprinast and inhaled nitric oxide abolishes hypoxic pulmonary hypertension.
Next Document:  Changes in cerebral venous prostanoids during midazolam-induced cerebrovascular hypotension in newbo...